Chemomab Therapeutics
CMMB
15 hedge funds and large institutions have $1.71M invested in Chemomab Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more funds holding
Funds holding: 15 → 15 (0)
0.01% less ownership
Funds ownership: 0.36% → 0.36% (-0.01%)
36% less capital invested
Capital invested by funds: $2.68M → $1.71M (-$971K)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$68.4K |
| 2 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$24.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15.7K |
| 4 |
Morgan Stanley
New York
|
+$1.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$129K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$71.5K |
| 3 |
State Street
Boston,
Massachusetts
|
-$24.3K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$12.7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.38K |
CMMB Hedge Fund Activity: Q3 2022 in Review
15 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2022, worth a combined $1.71M — down 36% from $2.68M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CMMB positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $68.4K. The largest seller was Meitav Investment House, exiting entirely with an estimated $129K sold.
- 15 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.71M of Chemomab Therapeutics stock for Q3 2022, down 36% quarter-over-quarter.
- 3 funds opened new Chemomab Therapeutics positions in Q3 2022 and 2 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $68.4K added.
- The largest Chemomab Therapeutics seller in Q3 2022 was Meitav Investment House, an estimated $129K sold.
Based on aggregated 13F filings for Q3 2022.